Prashant Reddy

Prashant Reddy

T. Prashant Reddy graduated from the National Law School of India University, Bangalore, with a B.A.LLB (Hons.) degree in 2008. He later graduated with a LLM degree (Law, Science & Technology) from the Stanford Law School in 2013. Prashant has worked with law firms in Delhi and in academia in India and Singapore. He is also co-author of the book Create, Copy, Disrupt: India's Intellectual Property Dilemmas (OUP).

Foreign pharma may adopt differential pricing at last


Unnikrishnan of the Mint recently reported that foreign pharma companies are finally ‘mulling’ over whether to adopt differential pricing for their drugs in India. The foreign drug makers plan to offer these medicines at different tiers of prices for government supply, patient access programmes, hospitals in rural areas and non-profit organizations, said an official with the Organisation of Pharmaceutical Producers of India (OPPI), an industry body that chiefly represents foreign drug firms present in India. The discussions are at an…


Read More »

Will the real NGO please stand up?


The Delhi High Court in its recent March 19thruling on the Roche-Cipla issue had lamented about the fact that it did not have access to any accurate information as to how many patients were affected by lung cancer and how many of them actually had access to Roche’s drug. A lack of quality empirical evidence has been a lamentable feature in all policy debates regarding patents in India. Three days after this judgment of the Delhi High Court a leading…


Read More »

Big Pharma and neglected diseases


The BS and the Mint recently carried stories on Pfizer’s announcement that it will focus its R&D efforts on diseases affecting developing countries such as India. As of now Pfizer seeks to target diseases such as cancer, diabetes, neurological disorders and inflammation, with special emphasis on the regional characteristics of the ailments. Pfizer will also work on certain vaccines and other unmet medical needs. However it remains to be seen whether Pfizer actually translates its words into actions or whether…


Read More »

SpicyIP Tidbit: BBMP seeks to patent construction technology


The Hindu reports that the BBMP or the Bruhat Bangalore Mahanagar Palike is seeking to patent a novel technology which allows it to build an underpass for a fraction of its previous cost. While the usual cost of an underpass is usually Rs. 20 crores the novel technology would reduce costs to a mere Rs. 1 crore! The other huge advantage of these underpasses is that they take significantly lesser time to construct – a huge advantage in congested cities…


Read More »

SpicyIP Tidbit: Frontline’s interview with Dr. Baltimore


The Frontline one of India’s last few leftist news magazines’ (The cover story last month was a tribute to the ‘Living Legend‘- Castro, the week after that the cover story was an attack on the ‘Neo-liberal policies‘ of the UPA Govt.) carried a superbly detailed interview of Nobel Laureate David Baltimore. Dr. Baltimore shared the Nobel Prize for Physiology or Medicine with Howard Temin and Renato Dulbecco at the young age of 37. At the time, Baltimore’s greatest contribution to…


Read More »

SpicyIP Tidbit: Cipla wins round one in its battle against Roche


The much awaited judgment of the Delhi High Court on the issue of temporary injunction in the Roche-Cipla case is finally out. Cipla’s risky strategy has paid off with the Delhi High Court allowing it to continue the manufacture of Erlotinib till a final ruling on the case. The only caveat that the Court attached was that Cipla maintain ‘fair accounts’ of the drugs sold so that it may adequately compensate Roche in case of an adverse final ruling. SpicyIP…


Read More »
Patent

USV wins appeal against USPTO decision.


The latest as reported by PharmaBiz.com and Business Line is that USV Ltd. an Indian Pharma company has won against an appeal against an Order of the USPTO over a drug salt donepezil oxalate. The appeal against the USPTO Order lay with the Board of Patent Appeals and Interferences which rendered its decision on Feb 5th, 2008. The decision is available on the website of the Board. The appeal was Appeal No. 2007-4478. At the examination stage the examiner had…


Read More »
Copyright

What’s the solution to YouTube’s infringing tactics?


Very recently Sumathi had informed us that the Utube-Tseries litigation may end because the parties seem to be headed for an out of court settlement. SpicyIP however was curious about how other countries are dealing with the growing complaints of copyright infringement against online content providers and decided to research a little on it. We dug up some mildly interesting material.Apparently late in 2007 Google Video had been held liable for copyright infringement of a documentary called ‘Tranquillity Bay’ by…


Read More »
Patent

SpicyIP Petition to bear fruit by early 2009


As most of you will recollect SpicyIP has been lamenting for some time now about the lack of a digitised database on patents granted by the Indian Patent Office. In an inspired bid to give vent to our collective frustrations on this matter Shamnad came up with the idea of sending a SpicyIP I-Petition to the Government of India in regards this sorry state of affairs. The SpicyIP I-Petition was a huge success because so many of you signed up,…


Read More »

Chinese pharma poses serious competition to Indian Pharma: PharmaBiz


PharmaBiz.com reports that Chinese pharmaceutical companies are posing a serious threat to their Indian counterparts. As usual the Chinese who are past-masters at reverse engineering have started manufacturing drugs at prices cheaper than Indian drugs. Active pharmaceutical ingredient (API) units in India have already faced severe competition in the country during the last ten years leading to several units shutting down but the threat now is to the formulations industry. The Indian pharmaceutical industry is lobbying hard to ensure that…


Read More »